pharma Archives - aHUS Alliance Action

Kamal is an aHUS Super Hero

Post author:Len Woodward
Post published:November 27, 2022
Post category:Uncategorized
Post comments:0 Comments

Kamal Shah is a Director/Trustee of aHUS alliance Global Action. He first had aHUS over 25 years ago. It was triggered…

aHUS Drug Candidates – the 2022 Landscape

Post author:Linda Burke
Post published:September 13, 2022
Post category:Featured
Post comments:0 Comments

What’s new in 2022 regarding expansion in atypical HUS knowledge, and advancements for investigational drugs which may have potential as new…

2020 Atypical Drug Discovery Review, released by the aHUS Alliance

Post author:ahusalliance
Post published:June 24, 2020
Post category:Uncategorized
Post comments:0 Comments

2020 overview of atypical HUS therapeutic drug development, by the aHUS Alliance

Small Molecule Factor D Inhibitors – Right for aHUS?

Post author:ahusalliance
Post published:October 9, 2019
Post category:Featured
Post comments:0 Comments

Out of more than 7000 rare diseases, only an estimated 5% have an approved treatment or therapy (Rare Disease Day, FAQs).…

OMS721: Omeros Research Collaboration with University of Cambridge

Post author:ahusalliance
Post published:December 13, 2018
Post category:Featured
Post comments:0 Comments

Pharma News: an Atypical HUS update from the aHUS Alliance. In its 11 December 2018 press release, the Omeros Corporation announced a new collaboration with a UK university to create the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR). Focus of the OC3IR will be research into OMS721 and OMS906, but how will it engage other aHUS stakeholders interested in OMS721 clinical trials and atypical HUS advancements in research?

Breaking Down Barriers in aHUS Clinical Trials

Post author:ahusalliance
Post published:October 18, 2018
Post category:Featured
Post comments:0 Comments

Break down in communication flows and fragmented outreach have built barriers for research and clinical trial enrollment regarding advancing new options for those with the rare disease atypical HUS (aHUS, or hemolytic uremic syndrome). The aHUS Alliance looks at current challenges, and potential pathways to explore and engage.